for people ages 18 years and up (full criteria)
at UC Irvine UCLA UCSD
study started
estimated completion
Principal Investigator
by Frederick E. Millard (ucsd)Mark S. Litwin (ucla)Cory Hugen (uci)
Photo of Frederick E. Millard
Frederick E. Millard



This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.

Official Title

A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors


PRIMARY OBJECTIVE: I. To estimate the positive predictive value within each of the early stage testicular seminoma and nonseminoma groups using plasma miRNA 371 expression at relapse to detect germ cell malignancy. SECONDARY OBJECTIVES: I. To bank prospectively obtained serial liquid biospecimens for low and moderate risk of relapse patients annotated by patient level clinical data. II. To bank prospectively collected, clinically annotated specimens for high risk patients and non-testicular primary patients in collaboration with Children's Oncology Group study AGCT 1531. OUTLINE: Patients undergo collection of blood every 3-6 months for up to 3 years.


Germ Cell Tumor Metachronous Malignant Neoplasm Seminoma Stage I Testicular Cancer AJCC v8 Stage IA Testicular Cancer AJCC v8 Stage IB Testicular Cancer AJCC v8 Stage IS Testicular Cancer AJCC v8 Neoplasms, Germ Cell and Embryonal Neoplasms Testicular Neoplasms Biomarker Analysis Blood Product Collection


For people ages 18 years and up

Inclusion Criteria:

  • Patients must have a new diagnosis of a germ cell tumor. confirmed pathologically or serologically (diagnostic elevation of human chorionic gonadotropin [HCG]/alpha-fetoprotein [AFP]). All primary sites, stages, histological subtypes of germ cell tumor are eligible. Metachronous second primary germ cell tumors are eligible
  • If surgery is planned, male patients with clinical stage I testicular cancer must have orchiectomy completed within 42 days prior to registration
  • Patients must be registered within 42 days after diagnosis and prior to initiation of a management plan or treatment for the disease
  • Patients must have initial imaging, laboratory and other clinical evaluations (see below) performed within 42 days prior to registration. Imaging reports, pathology reports and performance status will be collected
  • Patients must have beta-human chorionic gonadotropin (beta- HCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH) assessments within 42 days prior to registration
  • NOTE: If the patient had an orchiectomy prior to registration, report tumor marker values before and after surgery on the Baseline Tumor Marker form
  • Patients must have risk of relapse assessment determined by the local investigator prior to registration
  • Patients must agree to submit required specimens for defined translational medicine studies. These specimens are drawn at the same time as standard laboratory evaluations (beta-HCG, AFP, and LDH); NOTE: Ideally, patients should be willing to return to their center performing surveillance (registering site) for the duration of the study to ensure that specimens are timed to standard clinical observations (the registering site's surveillance schedule)
  • Patients must be offered participation in specimen banking for future research. With patient's consent, specimens must be submitted.
  • Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
  • As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system


  • UC San Diego Moores Cancer Center accepting new patients
    La Jolla California 92093 United States
  • UCLA / Jonsson Comprehensive Cancer Center accepting new patients
    Los Angeles California 90095 United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center accepting new patients
    Orange California 92868 United States
  • Kaiser Permanente-San Francisco accepting new patients
    San Francisco California 94115 United States
  • Kaiser Permanente West Los Angeles accepting new patients
    Los Angeles California 90034 United States
  • USC Norris Oncology/Hematology-Newport Beach accepting new patients
    Newport Beach California 92663 United States
  • Fresno Cancer Center accepting new patients
    Fresno California 93720 United States
  • Kaiser Permanente-Fresno accepting new patients
    Fresno California 93720 United States
  • Kaiser Permanente Cancer Treatment Center accepting new patients
    South San Francisco California 94080 United States
  • Kaiser Permanente-South San Francisco accepting new patients
    South San Francisco California 94080 United States

Lead Scientists at University of California Health

  • Frederick E. Millard (ucsd)
    Clinical Professor, Medicine.
  • Mark S. Litwin (ucla)
    Department Chair, Urology, Urology. Authored (or co-authored) 267 research publications.
  • Cory Hugen (uci)
    Associate Clinical Professor, Urology. Authored (or co-authored) 21 research publications.


accepting new patients
Start Date
Completion Date
Southwest Oncology Group
Study Type
Last Updated